<code id='065F534AE9'></code><style id='065F534AE9'></style>
    • <acronym id='065F534AE9'></acronym>
      <center id='065F534AE9'><center id='065F534AE9'><tfoot id='065F534AE9'></tfoot></center><abbr id='065F534AE9'><dir id='065F534AE9'><tfoot id='065F534AE9'></tfoot><noframes id='065F534AE9'>

    • <optgroup id='065F534AE9'><strike id='065F534AE9'><sup id='065F534AE9'></sup></strike><code id='065F534AE9'></code></optgroup>
        1. <b id='065F534AE9'><label id='065F534AE9'><select id='065F534AE9'><dt id='065F534AE9'><span id='065F534AE9'></span></dt></select></label></b><u id='065F534AE9'></u>
          <i id='065F534AE9'><strike id='065F534AE9'><tt id='065F534AE9'><pre id='065F534AE9'></pre></tt></strike></i>

          explore

          explore

          author:entertainment    Page View:67
          Sammy Kimball for STAT

          Is Wegovy really a brain drug? Which Alzheimer’s disease treatment works best? And what’s the point of Threads?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Megan Molteni joins us to explain the evolving science suggesting products like Wegovy are less weight loss drugs than treatments for human desire. We also explain why this summer is shaping up to be a pivotal moment for the treatment of Alzheimer’s and discuss our befuddlement with the latest social media platform.

          advertisement

          For more on what we cover, here’s the story on GLP-1 drugs and the brain; here’s the latest on Leqembi; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          comprehensive

          Hepatitis C has a cure — but many Americans still lack access to it
          Hepatitis C has a cure — but many Americans still lack access to it

          AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs

          read more
          Treeline, Josh Bilenker's next biotech, is cloaked in mystery
          Treeline, Josh Bilenker's next biotech, is cloaked in mystery

          APPhoto/TedS.WarrenJoshBilenker’slastcompany,LoxoOncology,waspurchasedbyEliLillyfor$8billion.Nosurpr

          read more
          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more

          In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

          AlastairGrant/APLONDON— AstraZenecasaidThursdayitwouldpurchasetheFrenchfirmAmolytPharmainadealworthu